1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031

Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031

  • February 2021
  • 338 pages
  • ID: 6061840
  • Format: PDF
  • Visiongain

Summary

Table of Contents

Forecasts by Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity, Other Disease Causes), by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc, Other Drug Type), by Sales Channel (Hospital Pharmacy, Online Suppliers, Retail Pharmacy, Other Sales Channel) AND Regional and Leading National Market Analysis PLUS Analysis of Leading NAFLD & NASH Companies AND COVID-19 Recovery Scenarios

What is holding you back in the Non-alcoholic Fatty Liver Disease & NASH Business?
NASH is presently diagnosed by methods such as blood test, imaging or a liver biopsy. These tests are time consuming and have less certainty as they are generic tests. Imaging techniques like CT, MRI and Ultrasound scans were inaccurate to diagnose NASH. These tests are not just incorrect for NASH diagnosis but also cost a lot. This absence of conclusive diagnostic methods in order to detect NASH, is the major challenge to the NASH market.
Our 330+ page report provides 275 tables, 191 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing non-alcoholic fatty liver disease & NASH market. Buy our report to see how to exploit these opportunities in the global market.
Forecasts to 2031 and other analyses reveal the commercial prospects
. In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
. You find original analyses, with business outlooks and developments.
. Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.
Discover sales predictions for the global non-alcoholic fatty liver disease & NASH market and submarkets
Along with revenue prediction for the overall world market, there are 5 segmentations of the non-alcoholic fatty liver disease & NASH market, with forecasts for 5 Disease Cause, 5 Drug Types, 3 Types, 4 Sales Channel each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.
Leading companies and the potential for market growth
As per the analysis, global non-alcoholic fatty liver disease & NASH market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

What all Segments Are Covered in the Report?
Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause (COVID-19 Impact Recovery Analysis Covered)
. Hypertension
. Heart Disease
. High Blood Lipid
. Type 2 Diabetes
. Obesity
. Other Disease Causes
Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type (COVID-19 Impact Recovery Analysis Covered)
. Vitamin E & Pioglitazone
. Ocaliva
. Elafibranor
. Selonsertib
. Cencicriviroc
. Other Drug Type
Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel (COVID-19 Impact Recovery Analysis Covered)
. Hospital Pharmacy
. Online Suppliers
. Retail Pharmacy
. Other Sales Channel
Global Non-alcoholic Fatty Liver Disease & NASH Market by Region (COVID-19 Impact Recovery Analysis Covered)
. North America
. Europe
. Asia-Pacific
. Latin America
. Middle East
. Africa
Need industry data? Please contact us today.
Which Key Players Are Leading the Global Market and how much Share do they Hold?

The global market for non-alcoholic fatty liver disease & NASH is ascending and has made significant gains in NASH treatments. The players in the non-alcoholic fatty liver disease & NASH market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
. Mergers and acquisitions.
. Product launches.
. Collaborations and partnerships.
Product approval is a major milestone facing all key competitors in the non-alcoholic fatty liver disease & NASH market. Several strategies were implemented by key market players between 2015 and Jan 2021. There are over 100 pharma companies involved in different aspects of NASH therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.
How the Non-alcoholic Fatty Liver Disease & NASH Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated
. What is the current size of the overall global non-alcoholic fatty liver disease & NASH market? How much will this market be worth from 2021 to 2031?
. How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
. Who are the leading companies and what are their activities, results, developments and prospects?
. What are some of the most prominent human non-alcoholic fatty liver disease & NASH currently in development?
. What are the main trends that will affect the world non-alcoholic fatty liver disease & NASH market between 2021 and 2031?
. What are the main strengths, weaknesses, opportunities and threats for the market?
. What are the social, technological, economic and political influences that will shape that industry over the next ten years?
. How will the global non-alcoholic fatty liver disease & NASH market evolve over the forecasted period, 2021 to 2031?
. Which NASH drugs and therapies can succeed and what revenues could they generate to 2031?
. What will be the main commercial drivers for the NASH market from 2021 to 2031?
. How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
. How will that industry evolve between 2021 and 2031, especially in R&D?
Top 20 Leading Players Profiled in the Report
. Pfizer Inc. (Pfizer)
. Roche Holding AG (Roche)
. Takeda Pharmaceutical Company Limited
. Intercept Pharmaceuticals, Inc.
. AstraZeneca PLC
. Novartis AG
. Merck & Co., Inc.
. AbbVie Inc. (AbbVie)
. Gilead Sciences, Inc.
. Genfit Biotechnology
. Cardax, Inc.
. Daewoong Co Ltd
. Madrigal Pharmaceuticals, Inc.,
. Mirum Pharmaceuticals, Inc.
. GW Pharmaceuticals plc.



Please note: This report is accessed through a password system. Single user (non-printable) and departmental licenses expires after 12 month period.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on